The company faces risks from the Change Healthcare cyberattack, including potential litigation, reputational damage, regulatory actions, and disruption to operations. Medicare Advantage funding reductions, Medicaid redeterminations, and potential changes in health care laws/regulations pose ongoing risks. The company's investment portfolio is subject to interest rate fluctuations, and there are uncertainties related to various legal proceedings and government investigations. The sale of South American operations also carries risks.
Financial Upside
Revenue growth is anticipated, primarily from Optum Rx and Optum Health, and domestic UnitedHealthcare offerings. The company's significant cash and cash equivalent balance, along with available-for-sale debt securities and equity securities, suggests strong liquidity. The company has issued new debt, and has a share repurchase program. Cost management initiatives and business dispositions are also potential positive factors.
